Plasma Clusterin and the Risk of Alzheimer Disease

被引:167
|
作者
Schrijvers, Elisabeth M. C. [1 ,2 ]
Koudstaal, Peter J. [2 ]
Hofman, Albert [1 ]
Breteler, Monique M. B. [1 ,3 ]
机构
[1] Univ Med Ctr, Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands
[2] Univ Med Ctr, Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands
[3] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany
来源
关键词
GENOME-WIDE ASSOCIATION; IDENTIFIES VARIANTS; APOLIPOPROTEIN-J; MENTAL STATE; DIAGNOSIS; DEMENTIA; CLU;
D O I
10.1001/jama.2011.381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Variants in the clusterin gene are associated with the risk of Alzheimer disease (AD) and clusterin levels have been found to be increased in brain and cerebrospinal fluid of patients with AD. Plasma clusterin was reported to be associated with brain atrophy, baseline disease severity, and rapid clinical progression in patients with AD. Objective To evaluate the potential of plasma clusterin as a biomarker of the presence, severity, and risk of AD. Design, Setting, and Participants A case-cohort study nested within the Rotterdam Study, a prospective population-based cohort study conducted in Rotterdam, the Netherlands. Plasma levels of clusterin were measured at baseline (1997-1999) in 60 individuals with prevalent AD, a random subcohort of 926 participants, and an additional 156 participants diagnosed with AD during follow-up until January 1, 2007 (mean [SD], 7.2 [2.3] years). Main Outcome Measures Prevalent AD, severity of AD measured by the Mini-Mental State Examination (MMSE) score, and the risk of developing AD during follow-up. Results The likelihood of prevalent AD increased with increasing plasma levels of clusterin (odds ratio [OR] per SD increase of plasma clusterin level, 1.63; 95% confidence interval [CI], 1.21-2.20; adjusted for age, sex, education level, apolipoprotein E status, diabetes, smoking, coronary heart disease, and hypertension). Among patients with AD, higher clusterin levels were associated with more severe disease (adjusted difference in MMSE score per SD increase in clusterin levels, -1.36; 95% CI, -2.70 to -0.02; P=.047). Plasma clusterin levels were not related to the risk of incident AD during total follow-up (adjusted HR, 1.00; 95% CI, 0.85-1.17; P for trend=.77) or within 3 years of baseline (adjusted HR, 1.09; 95% CI, 0.84-1.42; P for trend=.65). Conclusion Plasma clusterin levels were significantly associated with baseline prevalence and severity of AD, but not with incidence of AD. JAMA. 2011;305(13):1322-1326 www.jama.com
引用
收藏
页码:1322 / 1326
页数:5
相关论文
共 50 条
  • [1] Plasma Clusterin and the Risk of Alzheimer Disease: The Rotterdam Study
    Schrijvers, Elisabeth M. C.
    Koudstaal, Peter J.
    Hofman, Albert
    Breteler, Monique M. B.
    [J]. NEUROLOGY, 2011, 76 (09) : A550 - A551
  • [2] Association of the Alzheimer's Disease Clusterin Risk Allele with Plasma Clusterin Concentration
    Schuermann, Britta
    Wiese, Birgitt
    Bickel, Horst
    Weyerer, Siegfried
    Riedel-Heller, Steffi G.
    Pentzek, Michael
    Bachmann, Cadja
    Williams, Julie
    van den Bussche, Hendrik
    Maier, Wolfgang
    Jessen, Frank
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (03) : 421 - 424
  • [3] Alzheimer's Disease Plasma Clusterin as a suitable Biomarker?
    Bossenmayer, Susanne
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2011, 79 (09) : 494 - 494
  • [4] No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
    Silajdzic, Edina
    Minthon, Lennart
    Bjorkqvist, Maria
    Hansson, Oskar
    [J]. PLOS ONE, 2012, 7 (11):
  • [5] Plasma Clusterin as a Potential Link Between Diabetes and Alzheimer Disease
    Ha, Junghee
    Moon, Min Kyong
    Kim, Hyunjeong
    Park, Minsun
    Cho, So Yeon
    Lee, Jimin
    Lee, Jun-Young
    Kim, Eosu
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : 3058 - 3068
  • [6] Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk
    Ling, I-Fang
    Bhongsatiern, Jiraganya
    Simpson, James F.
    Fardo, David W.
    Estus, Steven
    [J]. PLOS ONE, 2012, 7 (04):
  • [7] CLUSTERIN IN ALZHEIMER'S DISEASE
    Wu, Zhong-Chen
    Yu, Jin-Tai
    Li, Yang
    Tan, Lan
    [J]. ADVANCES IN CLINICAL CHEMISTRY, VOL 56, 2012, 56 : 155 - 173
  • [8] Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease
    Thambisetty, Madhav
    Simmons, Andrew
    Velayudhan, Latha
    Hye, Abdul
    Campbell, James
    Zhang, Yi
    Wahlund, Lars-Olof
    Westman, Eric
    Kinsey, Anna
    Guntert, Andreas
    Proitsi, Petroula
    Powell, John
    Causevic, Mirsada
    Killick, Richard
    Lunnon, Katie
    Lynham, Steven
    Broadstock, Martin
    Choudhry, Fahd
    Howlett, David R.
    Williams, Robert J.
    Sharp, Sally I.
    Mitchelmore, Cathy
    Tunnard, Catherine
    Leung, Rufina
    Foy, Catherine
    O'Brien, Darragh
    Breen, Gerome
    Furney, Simon J.
    Ward, Malcolm
    Kloszewska, Iwona
    Mecocci, Patrizia
    Soininen, Hilkka
    Tsolaki, Magda
    Vellas, Bruno
    Hodges, Angela
    Murphy, Declan G. M.
    Parkins, Sue
    Richardson, Jill C.
    Resnick, Susan M.
    Ferrucci, Luigi
    Wong, Dean F.
    Zhou, Yun
    Muehlboeck, Sebastian
    Evans, Alan
    Francis, Paul T.
    Spenger, Christian
    Lovestone, Simon
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (07) : 739 - 748
  • [9] Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease
    Jongbloed, Wesley
    van Dijk, Karin D.
    Mulder, Sandra D.
    van de Berg, Wilma D. J.
    Blankenstein, Marinus A.
    van der Flier, Wiesje
    Veerhuis, Robert
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2015, 46 (04) : 1103 - 1110
  • [10] Clusterin polymorphisms and Alzheimer’s disease
    Jin-Tai Yu
    Lan Tan
    [J]. European Journal of Epidemiology, 2012, 27 : 757 - 758